Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Effect on discontinuation of aromatase inhibitors (AI) · women with early breast cancer
Summary of findings table ‐ Systemic therapy showed no clear difference in effect on discontinuation of aromatase inhibitors (AI) compared with control (low certainty).
1 finding from 1 review
Number of adverse events requiring discontinuation of treatment ‐ not reported · primary progressive multiple sclerosis
Ocrelizumab showed no clear difference in number of participants experiencing treatment discontinuation caused… compared with placebo (low certainty).
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · patients with relapsing‐remitting multiple sclerosis
Ocrelizumab may leads to lower number of participants experiencing treatment discontinuation caused… compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age
Clobazam (low, medium and high doses) plus ASMs leads to higher number of participants with adverse events leading to study… compared with placebo plus ASMs (high certainty).
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age
Felbamate plus ASMs showed no clear difference in number of participants with adverse events leading to study… compared with placebo plus ASMs (low certainty).
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age
Lamotrigine plus ASMs showed no clear difference in number of participants with adverse events leading to study… compared with placebo plus ASMs (low certainty).
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age
Rufinamide plus ASMs showed no clear difference in number of participants with adverse events leading to study… compared with placebo plus ASMs (low certainty).
1 finding from 1 review
Number of adverse events requiring discontinuation of treatment ‐ not reported · Lennox‐Gastaut syndrome, any age
Rufinamide plus ASMs showed no clear difference in number of participants with treatment‐emergent adverse events… compared with other ASM plus ASMs (low certainty).
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age
Cannabidiol (10 mg/kg and 20 mg/kg) plus ASMs leads to higher number of participants with adverse events leading to study… compared with placebo plus ASMs (high certainty).
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events ‐ temporary or permanent discontinuation/hospitalisation at final · primary membranous nephropathy in adults with nephrotic syndrome
Oral alkylating agents ± steroids may leads to higher adverse events ‐ temporary/permanent discontinuation or… compared with placebo/no treatment/steroids (low certainty).
1 finding from 1 review
Adverse events ‐ temporary or permanent discontinuation/hospitalisation at final · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether calcineurin inhibitors ± steroids changes adverse events ‐ temporary or permanent… compared with placebo/no treatment/supportive treatment/steroids (very low certainty).
1 finding from 1 review
Adverse events ‐ temporary or permanent discontinuation/hospitalisation at final · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether calcineurin inhibitors ± steroids changes adverse events ‐ temporary or permanent… compared with alkylating agents ± steroids (very low certainty).
1 finding from 1 review